Antibody Drug Conjugates with Amatoxin Derivatives for Cancer Treatment
Summary
Vivasor, Inc. has been granted European Patent EP3471771A1 covering antibody drug conjugates using amatoxin derivatives as cytotoxic payloads for the treatment of cancer, with publication occurring on 15 April 2026. The patent application EP3471771 claims priority based on earlier filings and lists four named inventors: ZHU Tong, ZHANG Hong, KHASANOV Alisher, and CHEN Gang. The designation covers 32 European contracting states including Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Sweden, and others.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.
What changed
European Patent Office publication EP3471771A1 grants Vivasor, Inc. patent protection for antibody drug conjugates in which amatoxin derivatives serve as the drug component, applicable to cancer treatment (A61P 35/00). The patent is designated across 32 European contracting states spanning the AL to TR designation range. IP rights holders and competitors in the oncology therapeutics space should monitor the patent's claims, particularly the conjugate structures (A61K 47/68) and associated linker-antibody configurations (C07K 16/32), for freedom-to-operate and licensing considerations.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTIBODY DRUG CONJUGATES HAVING DERIVATIVES OF AMATOXIN AS THE DRUG
Publication EP3471771A1 Kind: A1 Apr 15, 2026
Applicants
Vivasor, Inc.
Inventors
ZHU, Tong, ZHANG, Hong, KHASANOV, Alisher, CHEN, Gang
IPC Classifications
A61K 47/68 20170101AFI20200309BHEP A61K 39/395 20060101ALI20200309BHEP A61P 35/00 20060101ALI20200309BHEP C07K 19/00 20060101ALI20200309BHEP C07K 14/415 20060101ALI20200309BHEP C07K 16/32 20060101ALI20200309BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.